论文部分内容阅读
目的研究雌激素受体(ER)及孕激素受体(PR)的表达对于乳腺癌新辅助化疗(neoadjuvantchemotherapy,NACT)疗效的影响。方法采用免疫组化法检测52例乳腺癌组织中接受NACT前后的ER及PR的表达,分析ER、PR表达与NACT疗效的关系。结果 ER(-)患者NACT有效率为85.0%(17/20);ER(+)患者为56.3%(18/32),两组间差异有统计学意义(P(0.05);PR(-)患者NACT有效率为80%(21/25),PR(+)患者为51.6%(14/27),两组间差异有统计学意义(P(0.05)。结论 ER(-)及PR(-)乳腺癌患者在NACT中的获益分别较ER(+)及PR(+)者明显。测定激素受体的表达状态,可预测乳腺癌患者对NACT是否有效,初步指导肿瘤个体化辅助化疗。
Objective To investigate the effect of estrogen receptor (ER) and progesterone receptor (PR) expression on the efficacy of neoadjuvant chemotherapy (NACT) in breast cancer. Methods Immunohistochemistry was used to detect the expression of ER and PR in 52 cases of breast cancer before and after receiving NACT. The relationship between the expression of ER and PR and the efficacy of NACT was analyzed. Results The NACT efficiency was 85.0% (17/20) in ER (-) patients and 56.3% (18/32) in ER (+) patients. There was a significant difference between the two groups (P <0.05) The effective rate of NACT was 80% (21/25) in patients with PR (+) and 51.6% (14/27) in patients with PR (+), there was a significant difference between the two groups (P (0.05) ) The benefit of breast cancer patients in NACT was significantly higher than that of ER (+) and PR (+), respectively.Determination of hormone receptor expression could predict the effectiveness of NACT in breast cancer patients and initially guide the individualized adjuvant chemotherapy for cancer.